FDA Approves IBRANCE — Pfizer Laboratories Div Pfizer Inc

Pfizer received FDA approval for the oral breast cancer therapy Palbociclib (IBRANCE) on February 3, 2015, marking a significant entry into the rapidly expanding targeted oral oncology market by challenging established competition. The approval of this proprietary therapy is expected to significantly bolster Pfizer's oncology portfolio and drive substantial revenue growth across the global breast cancer treatment landscape.